Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081022 | 1.00 | TSHR (0.51) | TSHRMEN1KMT2ABIRC2CA14 | |
| SCHEMBL25967050 | 1.00 | TSHR (0.51) | TSHRMEN1KMT2ABIRC2CA14 | |
| SCHEMBL5571259 | 0.84 | METAP2 (0.45) | KMT2ACYP2C9L3MBTL1ALDH1A1 | |
| SCHEMBL28081927 | 0.84 | METAP2 (0.45) | KMT2ACYP2C9L3MBTL1ALDH1A1 | |
| SCHEMBL24967456 | 0.83 | CYP2C9 (0.42) | TSHRMEN1KMT2ABIRC2CYP2C9 | |
| SCHEMBL27393557 | 0.83 | METAP2 (0.44) | KMT2ACYP2C9L3MBTL1 | |
| SCHEMBL15479034 | 0.83 | TSHR (0.49) | TSHRMEN1KMT2ABIRC2CA14 | |
| SCHEMBL10986343 | 0.80 | TSHR (0.50) | TSHRMEN1KMT2ABIRC2CA14 | |
| SCHEMBL20335032 | 0.80 | TSHR (0.50) | TSHRMEN1KMT2ABIRC2CA14 | |
| SCHEMBL3673892 | 0.80 | TSHR (0.50) | TSHRMEN1KMT2ABIRC2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-113874080-B | IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-117820253-A | 3, 6-disubstituted benzothiazole compound and synthesis and application thereof | 西北农林科技大学 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024042018-A1 | A TOPICAL COMPOSITION COMPRISING CHLORINE E6 AND ZINC L-PYROGLUTAMATE | ZXA GROUP LTD. (BG) | 2024-02-29 | — | — | WO | disclosed |
| EP-4215530-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC Corporation (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | TSHR 173/4885MEN1 4271/4885KMT2A 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.